mst-1

IHMT-MST1-58 是一种 STE20-like protein 1 kinase (MST1) 抑制剂（IC50 ：23 nM），具有高效性、选择性和口服活性。IHMT-MST1-58 可用于研究 1 型或 2 型糖尿病。

XMU-MP-1是一种可逆且选择性的MST1/2激酶抑制剂，其对MST1和MST2的IC50值分别为71.1 nM和38.1 nM。

Cerdulatinib hydrochloride (PRT2070 hydrochloride) 是一种选择性可逆，具有口服活性、 ATP 竞争性的 SYK 和 JAK 的双重抑制剂，抑制 JAK1、2、3、SYK 和 Tyk2的 IC50值分别为12、6、8、32 和 0.5 nM。它可用于研究自身免疫性疾病和B 细胞恶性肿瘤。

Merestinib dihydrochloride (LY2801653 dihydrochloride) 是一种可口服的激酶抑制剂，具有抗肿瘤活性，抑制 MET、AXL、RON 和 MKNK1/2，抑制 NTRK 融合携带肿瘤的生长。

U-104 (NSC-213841) 是 CA IX 和 CA XII 碳酸酐酶 (CA) 抑制剂，其 Ki 分别为 45.1 nM 和 4.5 nM。小鼠模型中，它能够表现出明显的抑制肿瘤生长的作用。

Sobuzoxane (MST 16) 是一种口服活性拓扑异构酶 II (topoisomerase II) 抑制剂，导致细胞分裂不可逆抑制。它可用于研究对常规化疗耐药或复发的非霍奇金淋巴瘤。

Cerdulatinib (PRT2070) 是一种选择性 Tyk2抑制剂，IC50为 0.5 nM。它是 JAK 和 SYK 的双抑制剂，抑制JAK1、2、3 和SYK 的IC50分别为12、6、8 和 32。

HPK1-IN-7 是一种口服有活性的、有效的HPK1(造血祖细胞激酶1, MAP4K1) 抑制剂，其IC50值为2.6 nM，具有强大的家族及激酶组选择性。它对 IRAK4 (59 nM) 和 GLK (140 nM) 具有选择性。当它与抗 PD1联合使用时，对 MC38 同基因肿瘤模型表现出极大的疗效。

Anti-MST1R Antibody (MOR07692) 是一款人源化IgG1单克隆抗体，专门针对MST1R。

BMSpep-57 hydrochloride, a potent macrocyclic peptide, competitively inhibits PD-1/PD-L1 interaction, exhibiting an IC50 value of 7.68 nM. It binds to PD-L1 with dissociation constants (Kds) of 19 nM and 19.88 nM as determined by MST and SPR assays, respectively. This compound enhances T cell functionality by promoting IL-2 production in PBMCs[1].

hnRNPK-IN-1 is a specific ligand that binds to the heterogeneous nuclear ribonucleoprotein K (hnRNPK) with high affinity, evidenced by Kd values of 4.6 μM and 2.6 μM determined using surface plasmon resonance (SPR) and microscale thermophoresis (MST), respectively. This binding event leads to the disruption of hnRNPK's interaction with the c-myc promoter, resulting in the inhibition of c-myc transcription. Additionally, hnRNPK-IN-1 induces apoptosis in Hela cells and exhibits potent anti-tumor activities[1].

Amycolatopsin A is a macrolide polyketide originally isolated fromAmycolatopsisthat has antimycobacterial and anticancer activities.1It is active againstM. bovisandM. tuberculosis(IC50s = 0.4 and 4.4 μM, respectively) but notB. subtilis,S. aureus,E. coli, orP. aeruginosa(IC50s = >30 μM for all). Amycolatopsin A is cytotoxic to SW620 colorectal and NCI H460 lung cancer cells (IC50s = 0.08 and 1.2 μM, respectively). 1.Khalil, Z.G., Salim, A.A., Vuong, D., et al.Amycolatopsins A-C: Antimycobacterial glycosylated polyketide macrolides from the Australian soil Amycolatopsis sp. MST-108494J. Antibiot. (Tokyo)70(12)1097-1103(2017)

Amycolatopsin B is a bacterial metabolite originally isolated fromAmycolatopsisthat has anticancer activity.1It is cytotoxic to NCI H460 lung and SW620 colon cancer cells (IC50s = 0.28 and 0.14 μM, respectively). 1.Khalil, Z.G., Salim, A.A., Vuong, D., et al.Amycolatopsins A-C: Antimycobacterial glycosylated polyketide macrolides from the Australian soil Amycolatopsis sp. MST-108494J. Antibiot. (Tokyo)70(12)1097-1103(2017)

Amycolatopsin C is a polyketide macrolide originally isolated fromAmycolatopsisthat has antimycobacterial and anticancer activities.1It is active againstM. bovisandM. tuberculosis(IC50s = 2.7 and 5.7 μM, respectively) but notB. subtilis,S. aureus,E. coli, orP. aeruginosa(IC50s = >30 μM for all). Amycolatopsin C is cytotoxic to SW620 colorectal and NCI H460 lung cancer cells (IC50s = 10 and 5.9 μM, respectively). 1.Khalil, Z.G., Salim, A.A., Vuong, D., et al.Amycolatopsins A-C: Antimycobacterial glycosylated polyketide macrolides from the Australian soil Amycolatopsis sp. MST-108494J. Antibiot. (Tokyo)70(12)1097-1103(2017)

BMSpep-57, a potent macrocyclic peptide inhibitor, competitively disrupts the PD-1/PD-L1 interaction, demonstrating a significant inhibitory concentration (IC50) of 7.68 nM. It exhibits binding affinity towards PD-L1 with dissociation constants (Kd) of 19 nM and 19.88 nM in MicroScale Thermophoresis (MST) and Surface Plasmon Resonance (SPR) assays, respectively. This compound enhances T cell functionality by promoting Interleukin-2 (IL-2) production within Peripheral Blood Mononuclear Cells (PBMCs).